This invention discloses a pharmaceutical formula for arthritis treatment and/or prevention. The formula contains the following raw materials: a selenium-containing inorganic compound and a zinc-containing inorganic compound. The pharmaceutical formula described herein could be manufactured for topic application and provide a faster and safer treatment for various inflammatory joint pains. Pharmacodynamics results show that the invented pharmaceutical formula can significantly reduce the level of inflammatory cytokines in the joint synovial fluid in arthritis rabbit model, and the formulated ointment can achieve better efficacy compared with Voltaren™ (diclofenac) ointment; therefore the proposed formula has promising clinical application.

A method for improving holding power of an adhesive agent layer in a ropinirole-containing patch comprising a backing layer and the adhesive agent layer, wherein the adhesive agent layer contains at least one selected from the group consisting of ropinirole and a pharmaceutically acceptable salt thereof and an adhesive agent, the method comprising: causing the adhesive agent layer to further contain a sodium salt of carbonic acid.

Transdermal drug delivery systems and methods of fabricating such systems are provided. The active pharmaceutical ingredient can be lenalidomide or other immunomodulatory agents. More particularly, the present invention is directed to improving the solubility of lenalidomide and other immunomodulatory imide compounds and improving the permeation of such compounds through the skin.

The present disclosure relates to the transdermal administration of pharmaceutical agents, such as CBD, THC, psilocybin, psilocin, lysergic acid diethylamine (LSD), and/or ibogaine, and derivatives of these compounds, for the treatment and/or prevention and/or control of severe depression (treatment resistant), major depressive disorder, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, opioid addiction, anxiety (stress), adult ADHD, cluster headaches, and cancer related or other end-of-life psychological distress.

A ropinirole-containing patch comprising an adhesive agent layer and a backing layer, wherein the adhesive agent layer containing: at least one selected from the group consisting of ropinirole and a pharmaceutically acceptable salt thereof; a fatty acid metal salt having 7 or more carbon atoms; and an adhesive agent.

The present disclosure relates to the to the transdermal administration of active agents, such as diclofenac and/or CBD and/or THC, and derivatives of these compounds, for the treatment and/or prevention and/or control of chronic pain.

Methods, compositions of matter, and devices for delivering a therapeutic composition to a heart of a subject using a biopolymer scaffold material are described. In some embodiments, the biopolymer scaffold material including the therapeutic composition may be attached to a first cardiac tissue of a subject. The therapeutic composition is delivered from the biopolymer scaffold material to the heart of the subject.

A Transdermal Drug Delivery System (TDDS) of the reservoir or plaster or adhesive type for administrating Hydroxychloroquine and/or Chloroquine for the treatment of rheumatoid arthritis, lupus erythematosus, SARS CoV-2, porphyria cutanea tarda a for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7—day continuous application.

A composition for relieving pain, and methods of making and using the composition, whereby the composition comprises an amount of sugar or sugar alcohol; and an amount of vehicle; wherein the composition is formulated for transdermal administration; and wherein, upon transdermal administration, the composition is effective to relieve pain. As to particular embodiments, the composition further comprises an amount of alkalizing agent.

A method for creating a multi-antigen patch, comprising providing one or more transdermal patch sheets having a plurality of single dose transdermal patches residing thereon, wherein each one of the plurality of single dose transdermal patches includes an antigen at a particular dilution level disposed within a carrier, removing one or more of the plurality of single dose transdermal patches from the one or more transdermal patch sheets, adhering the one or more of the plurality of single dose transdermal patches to a backing, wherein the backing allows for multiple single dose transdermal patches to be adjacently adhered thereon, and covering the plurality of transdermal patches adhered to the backing with a peelable release liner.